Last reviewed · How we verify
NCT07421739
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
trial testing Non-interventional, digital, patient-reported, real-world study in Choroidal Melanoma in 15 participants. Currently enrolling.
15 August 2028
Quick facts
| Lead sponsor | Aura Biosciences |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 12 November 2025 |
| Primary completion | 15 August 2028 |
| Estimated completion | 15 August 2028 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Non-interventional, digital, patient-reported, real-world study
Conditions studied
- Choroidal Melanoma — all drugs for Choroidal Melanoma →
- Indeterminate Lesions — all drugs for Indeterminate Lesions →
- Uveal Melanoma — all drugs for Uveal Melanoma →
- Ocular Melanoma — all drugs for Ocular Melanoma →
Sponsor
Aura Biosciences — full company profile →
Who can join
Eligibility, any sex, with Choroidal Melanoma or Indeterminate Lesions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07421739
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Choroidal Melanoma
Currently open trials in the same condition.
- NCT06007690 — A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatm · Phase 3 · recruiting
Other Aura Biosciences trials
Trials by the same sponsor.
- NCT07338968 — A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma · not yet recruiting
- NCT06643884 — Suprachoroidal Administration in Subjects With Metastases to the Choroid · Phase 2 · recruiting
- NCT06007690 — A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatm · Phase 3 · recruiting
- NCT05266430 — Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeter · terminated
- NCT04417530 — Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Ind · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07421739 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aura Biosciences
- Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07421739.